New Rochelle, NY, June 5, 2015--In silico experiments demonstrate that advanced sensor and software technology that improves the accuracy of Continuous Glucose Monitoring (CGM) can enable better detection of dangerously low blood sugar and reduced frequency of hypoglycemic episodes. The significance of this direct relationship between the accuracy of CGM and a reduction in hypoglycemia is explored in a Commentary published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the DTT website until July 5, 2015.
Boris P. Kovatchev, PhD, University of Virginia Center for Diabetes Technology, Charlottesville, describes the results of in silico experiments his group performed to model and simulate the effect of glucose sensor error on glycemic control. The computer simulations used real data derived from studies of the original Dexcom G4 Platinum CGM system and the newer G4 Platinum with software version 505. The data provided a measure of the accuracy of the sensor in the hypoglycemic range. Dr. Kovatchev discusses the implications of the findings for continued adoption and future development of CGM in "Hypoglycemia Reduction and Accuracy of Continuous Glucose Monitoring."
"Accuracy of continuous glucose monitors is important especially for early detection of hypoglycemia and reliable closed-loop systems," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver.
The National Institute on Diabetes and Digestive and Kidney Diseases under Award Number DK085623 supported research reported in this publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes (ATTD) Conference.
The International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world's leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Diabetes Technology & Therapeutics